Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: The aim of this pilot study was to evaluate whether the uptake of 89Zr-bevacizumab in non-small cell lung cancer (NSCLC) tumors could be visualized and quantified. The correlation between tumor 89Zr-bevacizumab uptake and tumor response to antitumor therapy with a bevacizumab-based regimen was explored. Methods: Seven NSCLC patients underwent static PET scans at days 4 and 7 after injection of 36.4 ± 0.9 MBq (mean ± SD) 89Zr-bevacizumab, prior to commencing carboplatin-paclitaxel-bevacizumab chemotherapy (CPB). Overall survival (OS) and progression-free survival (PFS) to CPB followed by bevacizumab maintenance therapy was correlated to tumor tracer uptake, quantified using peak standardized uptake values (SUVpeak). Results: Zr-bevacizumab uptake (SUVpeak) was approximately four times higher in tumor tissues (primary tumor and metastases) than in non-tumor tissues (healthy muscle, lung, and fat) on days 4 and 7. A positive trend but no significant correlation could be found between SUVpeak and OS or PFS. Conclusions: This pilot study shows that 89Zr-bevacizumab PET imaging in NSCLC is feasible. Further investigation to validate this technique as a predictive biomarker for selecting patients for bevacizumab treatment is warranted.

Original languageEnglish
Article number35
Pages (from-to)1-7
Number of pages7
JournalEJNMMI Research
Volume4
Issue number1
DOIs
Publication statusPublished - 1 Dec 2014

Cite this

@article{186e6d1d35ae47c497c8aa5807aae3ef,
title = "Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer",
abstract = "Background: The aim of this pilot study was to evaluate whether the uptake of 89Zr-bevacizumab in non-small cell lung cancer (NSCLC) tumors could be visualized and quantified. The correlation between tumor 89Zr-bevacizumab uptake and tumor response to antitumor therapy with a bevacizumab-based regimen was explored. Methods: Seven NSCLC patients underwent static PET scans at days 4 and 7 after injection of 36.4 ± 0.9 MBq (mean ± SD) 89Zr-bevacizumab, prior to commencing carboplatin-paclitaxel-bevacizumab chemotherapy (CPB). Overall survival (OS) and progression-free survival (PFS) to CPB followed by bevacizumab maintenance therapy was correlated to tumor tracer uptake, quantified using peak standardized uptake values (SUVpeak). Results: Zr-bevacizumab uptake (SUVpeak) was approximately four times higher in tumor tissues (primary tumor and metastases) than in non-tumor tissues (healthy muscle, lung, and fat) on days 4 and 7. A positive trend but no significant correlation could be found between SUVpeak and OS or PFS. Conclusions: This pilot study shows that 89Zr-bevacizumab PET imaging in NSCLC is feasible. Further investigation to validate this technique as a predictive biomarker for selecting patients for bevacizumab treatment is warranted.",
keywords = "Zr-bevacizumab, Immuno-PET, NSCLC, VEGF",
author = "Idris Bahce and Huisman, {Marc C.} and Verwer, {Eline E.} and Rogier Ooijevaar and Firdaouss Boutkourt and Vugts, {Danielle J.} and {van Dongen}, {Guus A.M.S.} and Ronald Boellaard and Smit, {Egbert F.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1186/s13550-014-0035-5",
language = "English",
volume = "4",
pages = "1--7",
journal = "EJNMMI Research",
issn = "2191-219X",
publisher = "Springer Berlin",
number = "1",

}

TY - JOUR

T1 - Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer

AU - Bahce, Idris

AU - Huisman, Marc C.

AU - Verwer, Eline E.

AU - Ooijevaar, Rogier

AU - Boutkourt, Firdaouss

AU - Vugts, Danielle J.

AU - van Dongen, Guus A.M.S.

AU - Boellaard, Ronald

AU - Smit, Egbert F.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Background: The aim of this pilot study was to evaluate whether the uptake of 89Zr-bevacizumab in non-small cell lung cancer (NSCLC) tumors could be visualized and quantified. The correlation between tumor 89Zr-bevacizumab uptake and tumor response to antitumor therapy with a bevacizumab-based regimen was explored. Methods: Seven NSCLC patients underwent static PET scans at days 4 and 7 after injection of 36.4 ± 0.9 MBq (mean ± SD) 89Zr-bevacizumab, prior to commencing carboplatin-paclitaxel-bevacizumab chemotherapy (CPB). Overall survival (OS) and progression-free survival (PFS) to CPB followed by bevacizumab maintenance therapy was correlated to tumor tracer uptake, quantified using peak standardized uptake values (SUVpeak). Results: Zr-bevacizumab uptake (SUVpeak) was approximately four times higher in tumor tissues (primary tumor and metastases) than in non-tumor tissues (healthy muscle, lung, and fat) on days 4 and 7. A positive trend but no significant correlation could be found between SUVpeak and OS or PFS. Conclusions: This pilot study shows that 89Zr-bevacizumab PET imaging in NSCLC is feasible. Further investigation to validate this technique as a predictive biomarker for selecting patients for bevacizumab treatment is warranted.

AB - Background: The aim of this pilot study was to evaluate whether the uptake of 89Zr-bevacizumab in non-small cell lung cancer (NSCLC) tumors could be visualized and quantified. The correlation between tumor 89Zr-bevacizumab uptake and tumor response to antitumor therapy with a bevacizumab-based regimen was explored. Methods: Seven NSCLC patients underwent static PET scans at days 4 and 7 after injection of 36.4 ± 0.9 MBq (mean ± SD) 89Zr-bevacizumab, prior to commencing carboplatin-paclitaxel-bevacizumab chemotherapy (CPB). Overall survival (OS) and progression-free survival (PFS) to CPB followed by bevacizumab maintenance therapy was correlated to tumor tracer uptake, quantified using peak standardized uptake values (SUVpeak). Results: Zr-bevacizumab uptake (SUVpeak) was approximately four times higher in tumor tissues (primary tumor and metastases) than in non-tumor tissues (healthy muscle, lung, and fat) on days 4 and 7. A positive trend but no significant correlation could be found between SUVpeak and OS or PFS. Conclusions: This pilot study shows that 89Zr-bevacizumab PET imaging in NSCLC is feasible. Further investigation to validate this technique as a predictive biomarker for selecting patients for bevacizumab treatment is warranted.

KW - Zr-bevacizumab

KW - Immuno-PET

KW - NSCLC

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=85027942290&partnerID=8YFLogxK

U2 - 10.1186/s13550-014-0035-5

DO - 10.1186/s13550-014-0035-5

M3 - Article

VL - 4

SP - 1

EP - 7

JO - EJNMMI Research

JF - EJNMMI Research

SN - 2191-219X

IS - 1

M1 - 35

ER -